CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma

Joseph D. Malaer, Porunelloor Mathew

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

CS1 (also known as CD319, CRACC and SLAMF7) was identified as an NK cell receptor regulating immune functions. It is also expressed on B cells, T cells, Dendritic cells, NK-T cells, and monocytes. CS1 is overexpressed in multiple myeloma and makes it a target for immunotherapy. A humanized anti-CS1 antibody, Elotuzumab or Empliciti has shown promising results in clinical studies. This review focuses on the biology of CS1 in NK and other hematopoietic cells and multiple myeloma. Anti-CS1 mAb can activate natural cytotoxicity of NK cells as well as enhance ADCC (antibody-dependent cell-mediated cytotoxicity) and thus makes an effective target for immunotherapy of MM.

Original languageEnglish
Pages (from-to)1637-1641
Number of pages5
JournalAmerican Journal of Cancer Research
Volume7
Issue number8
StatePublished - 1 Jan 2017

Fingerprint

Multiple Myeloma
Natural Killer Cells
Immunotherapy
Natural Killer Cell Receptors
Antibody-Dependent Cell Cytotoxicity
T-Lymphocytes
Antibodies, Monoclonal, Humanized
Dendritic Cells
Monocytes
Anti-Idiotypic Antibodies
B-Lymphocytes
elotuzumab
Clinical Studies

Keywords

  • Antibody-based immunotherapy
  • CRACC
  • CS1
  • Elotuzumab
  • Multiple myeloma
  • SLAMF7

Cite this

@article{818eeea0986b48bbb488b765ae480701,
title = "CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma",
abstract = "CS1 (also known as CD319, CRACC and SLAMF7) was identified as an NK cell receptor regulating immune functions. It is also expressed on B cells, T cells, Dendritic cells, NK-T cells, and monocytes. CS1 is overexpressed in multiple myeloma and makes it a target for immunotherapy. A humanized anti-CS1 antibody, Elotuzumab or Empliciti has shown promising results in clinical studies. This review focuses on the biology of CS1 in NK and other hematopoietic cells and multiple myeloma. Anti-CS1 mAb can activate natural cytotoxicity of NK cells as well as enhance ADCC (antibody-dependent cell-mediated cytotoxicity) and thus makes an effective target for immunotherapy of MM.",
keywords = "Antibody-based immunotherapy, CRACC, CS1, Elotuzumab, Multiple myeloma, SLAMF7",
author = "Malaer, {Joseph D.} and Porunelloor Mathew",
year = "2017",
month = "1",
day = "1",
language = "English",
volume = "7",
pages = "1637--1641",
journal = "American Journal of Cancer Research",
issn = "2156-6976",
publisher = "e-Century Publishing Corporation",
number = "8",

}

CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma. / Malaer, Joseph D.; Mathew, Porunelloor.

In: American Journal of Cancer Research, Vol. 7, No. 8, 01.01.2017, p. 1637-1641.

Research output: Contribution to journalReview article

TY - JOUR

T1 - CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma

AU - Malaer, Joseph D.

AU - Mathew, Porunelloor

PY - 2017/1/1

Y1 - 2017/1/1

N2 - CS1 (also known as CD319, CRACC and SLAMF7) was identified as an NK cell receptor regulating immune functions. It is also expressed on B cells, T cells, Dendritic cells, NK-T cells, and monocytes. CS1 is overexpressed in multiple myeloma and makes it a target for immunotherapy. A humanized anti-CS1 antibody, Elotuzumab or Empliciti has shown promising results in clinical studies. This review focuses on the biology of CS1 in NK and other hematopoietic cells and multiple myeloma. Anti-CS1 mAb can activate natural cytotoxicity of NK cells as well as enhance ADCC (antibody-dependent cell-mediated cytotoxicity) and thus makes an effective target for immunotherapy of MM.

AB - CS1 (also known as CD319, CRACC and SLAMF7) was identified as an NK cell receptor regulating immune functions. It is also expressed on B cells, T cells, Dendritic cells, NK-T cells, and monocytes. CS1 is overexpressed in multiple myeloma and makes it a target for immunotherapy. A humanized anti-CS1 antibody, Elotuzumab or Empliciti has shown promising results in clinical studies. This review focuses on the biology of CS1 in NK and other hematopoietic cells and multiple myeloma. Anti-CS1 mAb can activate natural cytotoxicity of NK cells as well as enhance ADCC (antibody-dependent cell-mediated cytotoxicity) and thus makes an effective target for immunotherapy of MM.

KW - Antibody-based immunotherapy

KW - CRACC

KW - CS1

KW - Elotuzumab

KW - Multiple myeloma

KW - SLAMF7

UR - http://www.scopus.com/inward/record.url?scp=85028059141&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:85028059141

VL - 7

SP - 1637

EP - 1641

JO - American Journal of Cancer Research

JF - American Journal of Cancer Research

SN - 2156-6976

IS - 8

ER -